Sophie Guillonneau

Sophie Guillonneau

Auto-generated profile, based on publicly available information

Sophie Guillonneau

Sanofi, Chilly-Mazarin, France

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2019 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
LGLaure Gossec
Laure Gossec
VSVibeke Strand
Vibeke Strand
CPClare Proudfoot
Clare Proudfoot
CCChieh-I Chen
Chieh-I Chen
SGSophie Guillonneau
Sophie Guillonneau
MRMatthew Reaney
Matthew Reaney
Objective.: We evaluated the effect of sarilumab on patient-perceived impact of rheumatoid arthritis (RA) using the 7-domain RA Impact of Disease (RAID) scale. Methods.: Two phase III, randomized, controlled trials of sarilumab in patients with active, longstanding RA were analyzed: (1) sarilumab 150 mg and 200 mg every 2 weeks plus conventional synthetic disease-modifying antirheumatic drugs (+csDMARD) versus placebo + csDMARD [TARGET ( NCT01709578 )]; and (2) sarilumab 200 mg versus adalimumab (ADA) 40 mg monotherapy [MONARCH ( NCT02332590 )]. Least-squares mean (LSM) differences in RAID total score (range 0–10) and 7 key RA symptoms, including pain and fatigue (baseline to Weeks 12 and 24), were compared. “Responders” by RAID total score were defined by improvements from baseline ≥ minimal clinically important difference (MCID), and ≥ patient-acceptable symptom-state (PASS) at endpoint. Results.: Sarilumab 150 mg and 200 mg + csDMARD were nominally superior (p < 0.05) versus placebo + csDMARD and 200 mg sarilumab versus ADA 40 mg in LSM differences for RAID total score at weeks 12 (−0.93 and −1.13; −0.49, respectively) and 24 (−0.75 and −1.01; −0.78), and all effects of RA (except functional impairment in MONARCH Week 12). Effects were greater in physical domains (e.g., pain) than mental domains (e.g., emotional well-being). More patients receiving sarilumab versus placebo or ADA reported improvements ≥ MCID and PASS in total RAID scores at both assessments. Conclusion.: Based on the RAID, sarilumab + csDMARD or as monotherapy reduced the effect of RA on patients’ lives to a greater extent than placebo + csDMARD or ADA monotherapy. ( ClinicalTrials.gov : NCT01709578 and NCT02332590 )

15 September 2018 in European Respiratory Journal
Verified
Conference Paper
Closed access
WBWilliam Busse
William Busse
JMJorge F. Maspero
Jorge F. Maspero
CKContance H. Katelaris
Contance H. Katelaris
DSDinesh Saralaya
Dinesh Saralaya
SGSophie Guillonneau
Sophie Guillonneau
AKAsif Khan
Asif Khan
Background: Dupilumab (DPL), a fully human anti-IL-4Rα mAb that inhibits IL-4/IL-13, is approved for treatment of adults with inadequately controlled moderate-to-severe atopic dermatitis. In a phase 3 study (NCT02414854), asthma patients (pts) aged ≥12 years, with no minimum baseline (BL) eosinophil requirement, uncontrolled with medium-to-high-dose ICS, plus 1 or 2 controllers received DPL 200/300mg or placebo (PBO) every 2 weeks for 52 weeks. DPL reduced severe exacerbations, improved FEV1 and quality of life measures, and was generally well tolerated. Aim: Assess DPL effect on 22-item Sino-Nasal Outcome Test (SNOT-22) scores, a CRS disease-specific health-related quality of life (HRQoL) outcome, in asthma pts with CRS/NP. Methods: 382/1902 pts reported CRS/NP medical history. Outcome was change from BL in DPL vs PBO in SNOT-22 scores at Weeks 12, 24, and 52. Results: DPL improved SNOT-22 scores by Week 12, and over the 52-week treatment period (Table). SNOT-22 scores in the DPL-treated pts exceeded the minimal clinically important difference (≥8.9) at all time points compared to BL, and vs PBO at Week 52. The most common AE, with higher rates in 200/300mg DPL vs PBO, was injection-site reactions (21%/24% vs 6%/14%). Conclusion: Dupilumab significantly improved CRS/NP-specific symptoms and HRQoL in asthma pts with comorbid CRS/NP, and was generally well tolerated.